Avalo Therapeutics (AVTX) Competitors $9.29 -0.05 (-0.54%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.98 -0.31 (-3.38%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. ALMS, ARCT, EOLS, BCYC, TECX, NBTX, CGEM, MBX, PRME, and PRTAShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Alumis (ALMS), Arcturus Therapeutics (ARCT), Evolus (EOLS), Bicycle Therapeutics (BCYC), Tectonic Therapeutic (TECX), Nanobiotix (NBTX), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Prime Medicine (PRME), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Alumis Arcturus Therapeutics Evolus Bicycle Therapeutics Tectonic Therapeutic Nanobiotix Cullinan Therapeutics MBX Biosciences Prime Medicine Prothena Alumis (NASDAQ:ALMS) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, ALMS or AVTX? Alumis has a beta of -1.47, suggesting that its stock price is 247% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Does the media favor ALMS or AVTX? In the previous week, Avalo Therapeutics had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Avalo Therapeutics and 2 mentions for Alumis. Avalo Therapeutics' average media sentiment score of 0.96 beat Alumis' score of 0.94 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ALMS or AVTX more profitable? Avalo Therapeutics' return on equity of -48.48% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -119.15% -92.50% Avalo Therapeutics N/A -48.48%-35.94% Do institutionals and insiders have more ownership in ALMS or AVTX? 87.1% of Avalo Therapeutics shares are owned by institutional investors. 40.7% of Alumis shares are owned by company insiders. Comparatively, 3.0% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer ALMS or AVTX? Alumis presently has a consensus price target of $20.17, indicating a potential upside of 334.63%. Avalo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 222.93%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alumis is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, ALMS or AVTX? Avalo Therapeutics has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/AAvalo Therapeutics$440K277.64-$35.13MN/AN/A SummaryAvalo Therapeutics beats Alumis on 8 of the 12 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.18M$2.80B$5.75B$9.76BDividend YieldN/A1.69%4.10%4.04%P/E RatioN/A22.8083.2726.59Price / Sales277.64735.22535.09111.49Price / CashN/A174.6137.4459.26Price / Book1.175.9810.556.58Net Income-$35.13M$32.94M$3.27B$265.95M7 Day Performance-5.97%-1.28%0.40%0.17%1 Month Performance17.74%5.64%7.31%3.90%1 Year Performance32.71%-3.15%46.58%19.67% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.1224 of 5 stars$9.29-0.5%$30.00+222.9%+32.7%$122.18M$440K0.0040ALMSAlumis2.6669 of 5 stars$4.90+1.2%$20.17+311.6%-63.5%$503.67MN/A0.00N/AARCTArcturus Therapeutics2.8842 of 5 stars$17.71-4.3%$50.57+185.6%-19.4%$502.63M$152.31M-7.94180Positive NewsEOLSEvolus4.0908 of 5 stars$7.43-3.3%$21.25+186.0%-52.0%$496.78M$266.27M-7.58170Positive NewsBCYCBicycle Therapeutics3.449 of 5 stars$7.12+0.3%$22.22+212.1%-65.7%$491.70M$35.28M-2.03240News CoveragePositive NewsTECXTectonic Therapeutic2.3094 of 5 stars$24.57-6.1%$80.33+227.0%+33.0%$489.88MN/A-6.08120Positive NewsNBTXNanobiotix0.6411 of 5 stars$9.85-2.4%$8.00-18.8%+49.0%$483.95M-$11.61M0.00100Positive NewsCGEMCullinan Therapeutics1.9012 of 5 stars$7.64-6.7%$26.80+250.8%-61.5%$483.82MN/A-2.3730News CoveragePositive NewsMBXMBX BiosciencesN/A$13.89-3.1%N/AN/A$481.40MN/A-3.06N/APRMEPrime Medicine2.6168 of 5 stars$3.52-0.8%$8.92+153.3%-24.3%$473.70M$4.96M-1.72234PRTAProthena3.4265 of 5 stars$8.38-4.4%$30.25+261.0%-63.2%$472.09M$135.16M-1.49130News CoverageAnalyst Forecast Related Companies and Tools Related Companies Alumis Competitors Arcturus Therapeutics Competitors Evolus Competitors Bicycle Therapeutics Competitors Tectonic Therapeutic Competitors Nanobiotix Competitors Cullinan Therapeutics Competitors MBX Biosciences Competitors Prime Medicine Competitors Prothena Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
